MD Anderson and Replay announce FDA clearance of IND application...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a...
Cancer screening rates are significantly lower in U.S....
A national study led by researchers at The University of Texas MD Anderson Cancer Center and The University of New Mexico (UNM)...
MD Anderson and RUSH Unveil RUSH MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center and RUSH University System for Health today announced a partnership to create RUSH...
MD Anderson Research Highlights for April 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Study opens new avenue for immunotherapy drug development
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have...
Four MD Anderson researchers elected AAAS Fellows
HOUSTON ― In recognition of their significant achievements in the realm of cancer care and research, four researchers at The...
MD Anderson and CureVac enter strategic collaboration to...
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop...
MD Anderson Research Highlights for April 12, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
AACR: Trio of studies highlights promising early results...
ABSTRACTS CT037, CT038, CT042
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson...
AACR: PARP1-selective inhibitor demonstrates early efficacy...
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in...
AACR: Combination treatment is well-tolerated, shows...
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in...
AACR: Novel immunotherapies show promise for patients with...
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a...
MD Anderson Research Highlights AACR 2024 Special Edition
ABSTRACTS: 1212, 1227, 1244, 1283, CT030, 3893, 3922, 3930, 3942, 6620
The University of Texas MD Anderson Cancer Center’s Research...
Radiation before mastectomy cuts time delays for...
Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to...
AACR: MD Anderson’s Scott Kopetz and Elizabeth Travis...
Two researchers from The University of Texas MD Anderson Cancer Center will be honored with Scientific Achievement Awards at the...
AACR: MD Anderson's Padmanee Sharma elected Fellow of the...
Padmanee Sharma, M.D., Ph.D., associate vice president of Immunobiology, professor of Genitourinary Medical Oncology and Immunology,...